TABLE 3.

Univariate and multivariate Cox hazards analysis for 3-year overall survival of all patients with hepatocellular carcinoma.

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Huaier treatment	0.32 (0.24–0.41)	< 0.001	0.42 (0.32–0.57)	0.015
Age, y	1.01 (1.00–1.02)	< 0.001
Gender (male vs. female)	0.91 (0.74–1.11)	0.369
Cirrhosis (yes vs. no)	1.51 (1.14–2.11)	0.004
Hypertension (yes vs. no)	1.06 (0.99–1.03)	0.118
Diabetes (yes vs. no)	1.18 (0.76–1.82)	0.456
MELD score	1.07 (1.06–1.08)	< 0.001	1.02 (1.00–1.03)	0.021
ALT, IU/L	1.01 (1.01–1.02)	< 0.001
AST, IU/L	1.01 (1.01–1.01)	< 0.001
TBIL, μmol/L	1.04 (1.03–1.05)	< 0.001	1.01 (1.00–1.02)	0.012
ALB, g/L	0.92 (0.91–0.93)	< 0.001	0.96 (0.94–0.98)	< 0.001
γ-GGT, IU/L	1.01 (1.01–1.02)	< 0.001	1.01 (1.00–1.01)	0.002
Platelets, 109/L	1.03 (1.02–1.05)	< 0.001	1.03 (1.02–1.04)	< 0.001
Cr, µmol/L	1.01 (1.01–1.02)	< 0.001
INR	5.27 (4.29–6.47)	< 0.001	2.09 (1.51–2.91)	< 0.001
AFP, ng/mL (≥400 vs. < 400)	2.94 (2.46–3.51)	< 0.001	1.73 (1.42–2.11)	< 0.001
Tumor size, cm (≥5 vs. < 5)	4.22 (3.53–5.04)	< 0.001
Tumor multiplicity (multiple vs. solitary)	2.77 (2.31–3.32)	< 0.001	1.51 (1.19–1.96)	0.001
BCLC staging (C-D vs. 0-B)	5.21 (4.32–6.26)	< 0.001	2.18 (1.75–2.71)	< 0.001
Type of treatment
Resection	0.12 (0.08–0.17)	< 0.001	0.50 (0.31–0.78)	0.003
Minimally invasive	0.11 (0.09–0.14)	< 0.001	0.27 (0.20–0.37)	< 0.001
Palliative	References

Abbreviations: MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; γ-GGT, γ-glutamyl transferase; Cr, creatinine; INR, international normalized ratio; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer. Bold values: p < 0.05.